Table 1 Demographic and clinical data description
From: Oral vitamin A supplementation for ROP prevention in VLBW preterm infants
Vitamin A Supplemented infants N = 31 | Control infants N = 31 | P | |
|---|---|---|---|
Maternal age, years, mean (SD) | 33 (7) | 32 (4.8) | 0.6 |
Gestational age, weeks, mean (SD) | 29 (2.33) | 29 (2.66) | 0.6 |
Anthropometric data at birth, | |||
Weight (g), mean (SD) | 1134 (327) | 1097 (234) | 0.6 |
Length, (cm) mean (SD) | 36.5 (3.4) | 36.4 (2.8) | 0.9 |
Head circumference, (cm) mean (SD) | 25.8 (2.5) | 25.9 (2.3) | 0.8 |
SGA n (%) | 7 (22.5) | 7 (22.5) | 1 |
IUGR n (%) | 4 (12.9) | 7 (22.5) | 0.3 |
Male n (%) | 16 (51.6) | 19 (62.5) | 0.4 |
Female n (%) | 15 (48.4) | 12 (37.5) | |
Mode of delivery, n (%) | |||
vaginal delivery | 5 (16) | 9 (28.1) | 0.2 |
caesarean section | 26 (84) | 22 (71.9) | |
Apgar score at 1, mean (SD) | 5.1 (2.4) | 5.5 (2.1) | 0.5 |
Apgar score at 5, mean (SD) | 7.2 (2.2) | 7.5 (1.6) | 0.6 |
Stay in NICU, days, median (IQR) | 57 (44–107) | 69 (45–100) | 0.6 |
Oxygen therapy, days, median (IQR) | 26 (10–56) | 27 (12–56) | 0.7 |
Mechanical ventilation, days, median (IQR) | 3 (1–7) | 7 (1–17) | 0.4 |
CPAP, days, median (IQR) | 9.5 (4–33) | 12.5 (6–41) | 0.6 |
BPD n (%) | 13 (41.9) | 17 (54.9) | 0.4 |
NEC n (%) | 0 (0) | 1 (3.3) | 0.3 |
LOS n (%) | 1 (3.2) | 1 (3.2) | 1 |
IVH grade ≥ 2 n (%) | 0 | 4 (12.9) | 0.1 |
ROP n (%) | |||
No ROP | 22 (71.0) | 21 (67.7) | |
ROP grade 1 | 9 (29.0) | 4 (12.9) | 0.018 |
ROP grade ≥ 2 (with plus disease) | 0 | 6 (19.4) | |
ROP grade ≥ 2 n (%) | |||
No treatment | 1 (16.7) | ||
Laser | 2 (33.3) | ||
Anti-VEGF | 1 (16.7) | ||
Anti-VEGF and laser | 2 (33.3) | ||